A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Summary

To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

Timeline

Start

2024-09-14

Primary completion

2025-01-16

Completion

2025-03-06

Publications

• He LX, Yang L, Xiao ZK, Qiu R, Yu FM, Wu LQ, Zhang WH, Liu XC, Min LF, Ma XQ, Jiang JZ, Yuan B, Dai RR, Liu D, Li XH, Wang T, Cao J, Luo XB, Liu XJ, Chen C, Li WG, Yu D, Luo Z, Li WM; PACER-II Trial Investigators. Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial. Chest. 2026 Jun;169(6):1536-1550. doi: 10.1016/j.chest.2025.12.055. Epub 2026 Mar 3.

Drugs

Indications